Crinetics to highlight neuroendocrine tumor research progress at the 2025 north american neuroendocrine tumor society annual meeting

Preliminary analysis of one-year progression-free survival data from phase 2 study of novel sst2 agonist paltusotine under investigation for carcinoid syndrome demonstrated potential anti-tumor effects preliminary analysis of one-year progression-free survival data from phase 2 study of novel sst2 agonist paltusotine under investigation for carcinoid syndrome demonstrated potential anti-tumor effects
SST Ratings Summary
SST Quant Ranking